Please Wait
Applying Filters...
menu
    • menu
    PharmaCompass Sponsored Ads

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    Sigma-Aldrich empowers scientific discovery with top-quality solutions to accelerate research, innovation, and better health worldwide.

    Virtual Booth

    Contact Supplier

    PharmaCompass Sponsored Ads

    Virtual Booth

    Contact Supplier

    TransoPharm USA works in the Sourcing and Management of Active Pharmaceutical Ingredients.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    An Enquiry

    Menu

    Riociguat

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Filters Filter
    Cross PopUp
    FILTER :

    filter clear-filterReset all filters

    01 16Adempas

    02 3Alliance revenue - Adempas/Verquvo

    PharmaCompass
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    01

    Brand Name : Adempas

    Germany
    arrow
    PEGS Boston Summit
    Not Confirmed

    Bayer

    Riociguat

    Main Therapeutic Indication : Cardiovascular Diseases

    Currency : USD

    2020 Revenue in Millions : 760

    2019 Revenue in Millions : 506

    Growth (%) : 50

    Company Banner

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Brand Name : Adempas

    Germany
    arrow
    PEGS Boston Summit
    Not Confirmed

    Bayer

    Riociguat

    Main Therapeutic Indication : Cardiovascular Diseases

    Currency : USD

    2021 Revenue in Millions : 813

    2020 Revenue in Millions : 760

    Growth (%) : 18

    Company Banner

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Brand Name : Adempas

    Germany
    arrow
    PEGS Boston Summit
    Not Confirmed

    Bayer

    Riociguat

    Main Therapeutic Indication : Cardiology/Vascular Diseases

    Currency : USD

    2022 Revenue in Millions : 685

    2021 Revenue in Millions : 813

    Growth (%) : -16

    Company Banner

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    Brand Name : Adempas

    Germany
    arrow
    PEGS Boston Summit
    Not Confirmed

    Bayer

    Riociguat

    Main Therapeutic Indication : Cardiology/Vascular Diseases

    Currency : USD

    2023 Revenue in Millions : 716

    2022 Revenue in Millions : 685

    Growth (%) : 1

    Company Banner

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    Brand Name : Adempas

    Germany
    arrow
    PEGS Boston Summit
    Not Confirmed

    Bayer

    Riociguat

    Main Therapeutic Indication : Cardiology/Vascular Diseases

    Currency : USD

    2024 Revenue in Millions : 759

    2023 Revenue in Millions : 716

    Growth (%) : 6

    Company Banner

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    Brand Name : Adempas

    Germany
    arrow
    PEGS Boston Summit
    Not Confirmed

    Bayer

    Riociguat

    Main Therapeutic Indication : Cardiovascular Diseases

    Currency : USD

    2017 Revenue in Millions : 366

    2016 Revenue in Millions : 315

    Growth (%) : 16

    Company Banner

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    07

    Brand Name : Adempas

    Germany
    arrow
    PEGS Boston Summit
    Not Confirmed

    Bayer

    Riociguat

    Main Therapeutic Indication : Cardiovascular Diseases

    Currency : USD

    2018 Revenue in Millions : 402

    2017 Revenue in Millions : 333

    Growth (%) : 21%

    Company Banner

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    08

    Brand Name : Adempas

    Germany
    arrow
    PEGS Boston Summit
    Not Confirmed

    Bayer

    Riociguat

    Main Therapeutic Indication : Cardiovascular Diseases

    Currency : USD

    2019 Revenue in Millions : 456

    2018 Revenue in Millions : 388

    Growth (%) : 17

    Company Banner

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    09

    Brand Name : Adempas

    Riociguat

    arrow
    PEGS Boston Summit
    Not Confirmed

    Brand Name : Adempas

    U.S.A
    arrow
    PEGS Boston Summit
    Not Confirmed

    Merck

    Riociguat

    Main Therapeutic Indication : Cardiovascular Diseases

    Currency : USD

    2020 Revenue in Millions : 501

    2019 Revenue in Millions : 419

    Growth (%) : 20

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    10

    Brand Name : Adempas

    Riociguat

    arrow
    PEGS Boston Summit
    Not Confirmed

    Brand Name : Adempas

    U.S.A
    arrow
    PEGS Boston Summit
    Not Confirmed

    Merck

    Riociguat

    Main Therapeutic Indication : Cardiovascular Diseases

    Currency : USD

    2021 Revenue in Millions : 252

    2020 Revenue in Millions : 220

    Growth (%) : 15

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.